Damien Conover is the Director of Healthcare Equity Research at Morningstar. With a focus on the healthcare industry, Damien provides analysis and insights on various companies and their performance in the market. His articles cover a range of topics including valuations, acquisitions, drug developments, and financial performance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/ECVXZPYGAJEWHOXQMUK6RKDJOM.jpg)
By: Damien Conover
We've increased our fair value estimate of AbbVie stock. Securities In This Article Key Morningstar Metrics for AbbVie
By: Damien Conover
What we Thought of AstraZeneca's Q2 Earnings We are holding steady to our £124/$78 fair value estimates (local/ADR) for AstraZeneca ( AZN ) following
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/7PSSXPX6Q5FTBIWUUKWB7F7UOM.png)
By: Damien Conover
Pfizer's stock remains undervalued, in our view. Securities In This Article Key Morningstar Metrics for Pfizer
/cloudfront-us-east-1.images.arcpublishing.com/morningstar/B26QQUGWL5BVLMVULGYK3QQASI.jpg)
By: Damien Conover
With Cardiometabolic drug sales growing, here's what we think of Lilly's stock. Eli Lilly LLY is set to release its second-quarter earnings results on Aug. 8.
By: Damien Conover
Business Strategy and Outlook Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set
Increasing our fair value estimate of Eli Lilly's stock. Key Morningstar Metrics for Eli Lilly What We Thought of Eli Lilly's Earnings
While we are bullish on Lilly's sales prospects, the market may be overly optimistic.
By: Damien Conover
Business Strategy and Outlook AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat.
By: Damien Conover
Business Strategy and Outlook Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term.
By: Damien Conover
Business Strategy and Outlook With strong positions in multiple key therapeutic areas, Novartis is well positioned for steady long-term cash flows.
(833) 317-6278 
